Amneal Pharmaceuticals (AMRX) reported Q1 adjusted earnings Friday of $0.21 per diluted share, up from $0.14 a year earlier.
Three analysts polled by FactSet expected $0.15.
Revenue for the quarter ended March 31 was $695.4 million compared with $659.2 million a year earlier.
Three analysts surveyed by FactSet expected $714.8 million.
The company affirmed its 2025 adjusted earnings guidance of $0.65 to $0.70 per diluted share on revenue of $3 billion to $3.1 billion. Three analysts surveyed by FactSet expect adjusted earnings of $0.68 on sales of $3.03 billion.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。